The Spectranetics Corp

The Spectranetics — Spectranetics — Charing Cross 2016

19 slides from The Spectranetics's conference presentation, Apr 26, 2016

  1. Slide 1: ILLUMENATE Global Study Interim Analysis

    Charing Cross 2016 Prof. Thomas Zeller Department of Angiology University Heart Center Freiburg‐ Bad Krozingen Bad Krozingen, Germany On behalf of Dr. Andrew Holden, Prof. Yann Gouëffic and the ILLUMENATE Global Investigators ILLUMENATE Global Study Interim Analysis

  2. Slide 2: Disclosure

    Charing Cross 2016 Disclosure Speaker name: Prof. Thomas Zeller .................................................................................  I have the following potential conflicts of interest to report:  Receipt of grants/research support  Receipt of honoraria and travel support  Partici

  3. Slide 3: ILLUMENATE (SFA) Clinical Program: 6 Studies, 6000+ Patients

    Charing Cross 2016 ILLUMENATE (SFA) Clinical Program 6 Studies: 6000+ Patients

  4. Slide 4: ILLUMENATE Global Study Overview

    Charing Cross 2016 ILLUMENATE Global Study Overview  Prospective, multi‐center, single‐arm, study  Patients will be followed for up to 5 years Same rigorous data collection process as randomized trials, independent adjudication by: • Angiographic Core Laboratory1 • Duplex Ultrasound Core Laborator

  5. Slide 5: ILLUMENATE Global Study Overview: Objective and Endpoints

    Charing Cross 2016 ILLUMENATE Global Study Overview  Study Objective: Assess safety and performance of the Stellarex DCB in the SFA and/or popliteal arteries  Primary Safety Endpoint: Freedom from device‐ and procedure‐related death through 30 days and freedom from target limb major amputation and

  6. Slide 6: Study Device: Stellarex DCB

    Charing Cross 2016 • Low dose paclitaxel, 2 µg/mm2 • Excipient: Polyethylene Glycol (PEG) • Proprietary open‐folded coating technology • High coating stability • Limited drug loss • Effective drug tissue transfer and residency ( 28 days) Stellarex (2 µgr/mm2) DCB Comp. A (3.5 µgr/mm2) DCB Comp. B (

  7. Slide 7: Key Patient Eligibility Criteria

    Charing Cross 2016 Key Patient Eligibility Criteria Inclusion Criteria • Rutherford class 2, 3 or 4 • SFA and/or popliteal (down to trifurcation) • Has at least one patent run‐ off below‐the‐knee • 1 or 2 target lesion(s) with cumulative length ≤ 20 cm • Target vessel reference diameter 4‐6 mm Exclu

  8. Slide 8: Interim Analysis

    Charing Cross 2016 Interim Analysis  The following Interim analysis includes data on the first 153 subjects who have been seen for their 12 month follow‐up visit  N=153 subjects (of the 371 enrolled)  All presented data/images were monitored, adjudicated and assessed by the appropriate core lab a

  9. Slide 9: Baseline Patient Characteristics

    Charing Cross 2016 Baseline Patient Characteristics N (patients) 153 Age 69.3 ± 9.6 (153) Male 72.5% (111/153) Diabetes 35.3% (54/153) Body Mass Index 27.1 ± 4.1 (152) Hypertension 75.8% (116/153) Hyperlipidemia 75.8% (116/153) Current smoker 37.3% (57/153) Previous coronary revasc. 37.3% (57/153) R

  10. Slide 10: Baseline Angiographic Characteristics

    Charing Cross 2016 Baseline Angiographic Characteristics N (lesions) 174 De novo1 94.3% (164/174) Lesion Length (cm) 7.3 ± 5.0 (172) Total occlusions 25.6% (44/172) Calcification None/Mild 37.8% (65/172) Moderate 19.8% (34/172) Severe calcification2 42.4% (73/172) Minimum lumen diameter (mm) 1.1 ± 0

  11. Slide 11: Procedural Characteristics

    Charing Cross 2016 Procedural Characteristics Pre‐dilatation1 98.9% (172/174) Post‐dilatation1 25.3% (44/174) Provisional stent1 12.6% (22/174) Stent Due to Dissection1 7.5% (13/174) Post‐procedural Dissections Grade D Flow‐limiting (Grade E or F) 16.3% (28/172) 0% (0/172) Post‐procedure MLD (mm) 3.

  12. Slide 12: Interim 12-Month Safety Outcomes

    Charing Cross 2016 Interim 12 Month Safety Outcomes  Freedom from Primary Safety Event: 91.0%  12‐month all‐cause mortality rate: 0.7% (1/143)  Cause of death: pancreatic cancer Primary Safety Outcome Component Device‐ or procedure‐related death 0 Major target limb amputation 1 (Patient RCC 5 at

  13. Slide 13: Freedom From CD-TLR by Clinical Events Committee Adjudication

    Charing Cross 2016 Freedom From CD‐TLR* by Clinical Events Committee Adjudication * Defined as revascularization associated with PSVR ≥ 2.5 or >50% stenosis via angiogram and worsening of RCC by more than 1 or ABI decrease of >0.15 from the maximum early post-procedure level, that is clearly referab

  14. Slide 14: Freedom From Loss of Primary Patency by Duplex Core Lab Evaluation

    Charing Cross 2016 Freedom From Loss of Primary Patency by Duplex Core Lab Evaluation Primary Patency defined as freedom from Duplex derived restenosis (PSVR ≤ 2.5) and clinically-driven TLR Number at risk at day 395 is 39 since follow-up is still in progress Day 0 30 360 365 395 At Risk 174 171 161

  15. Slide 15: ILLUMENATE Global Interim Data In Context with Core Lab Adjudicated Patency Rates

    Charing Cross 2016 ILLUMENATE Global Interim Data In Context with Core Lab* Adjudicated Patency Rates Schroeder H, et al. Catheter Cadiovasc Interv 86;278‐286 (2015). Tepe G. IN.PACT SFA 1‐year primary outcomes. Oral presentation . Charing Cross. April 5–8, 2014. London, UK, 2014. Rosenfield K, Jaff

  16. Slide 16: Functional Outcomes: ABI and Rutherford Classification

    Charing Cross 2016 0% 1% 30% 57% 8% 4% 63% 23% 7% 6% 0% 1% RCC 0 RCC 1 RCC 2 RCC 3 RCC 4 RCC 5 Baseline 12 Months Functional Outcomes 0.72 0.93 0.92 0 0.2 0.4 0.6 0.8 1 1.2 Baseline n=139 6 months n=125 12 months n=121 Mean ABI Rutherford Classification*  74.8% of subjects had an improvement in ABI

  17. Slide 17: Functional Outcomes: Walking Impairment Questionnaire (WIQ)

    Charing Cross 2016 Functional Outcomes: Walking Impairment Questionnaire (WIQ) Mean WIQ Scores* *analysis includes only patients with WIQ data at baseline and 12 months (n=135) 29.4 22.7 41.2 30.9 71.9 48.6 64.2 61.2 Walking Distance Score Walking Speed Score Stair Climbing Score Composite WIQ Score

  18. Slide 18: Conclusions

    Charing Cross 2016 Conclusions • Interim 12‐Month patency rate: 88.5% at day 360 and 84.7% at day 365 • Consistent with ILLUMENATE FIH • Matching best‐in‐class reported outcomes to date • Interim 12‐Month CD‐TLR Free rate: 91.0% • Significant gains in functional outcomes achieved • No safety signals

  19. Slide 19: ILLUMENATE Global Study Interim Analysis

    Charing Cross 2016 Prof. Thomas Zeller Department of Angiology University Heart Center Freiburg‐ Bad Krozingen Bad Krozingen, Germany On behalf of Dr. Andrew Holden, Prof. Yann Gouëffic and the ILLUMENATE Global Investigators ILLUMENATE Global Study Interim Analysis

Spectranetics — Charing Cross 2016 on 6ix